Podcast
0.25 CME/CE Credit
Cystic Fibrosis: The Primary Care Provider’s Role in Case Finding and Referral
“Cystic Fibrosis: The Primary care Provider’s Role in Case Finding and Referral” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. Marrah Lachowicz-Scroggins, Program Director with NHLBI’s Division of Lung Diseases, and Dr. Deepika Polineni, director of the Cystic Fibrosis Center, Washington University School of Medicine in St. Louis. We’ll be discussing what general practitioners should know about cystic fibrosis, including the factors that contribute to delayed or missed diagnosis, and the similarities and differences with primary ciliary dyskinesia, or PCD.
Already listened on another platform?
CME/CE Information
0.25 AMA PRA Category 1 Credits™
Release Date: 9/5/2023
Expiration Date: 5/31/2025
Topics
Learning Objectives
- Identify the factors contributing to delayed or missed diagnosis of cystic fibrosis (CF) in the primary care setting
- Describe the common symptoms and profile of individuals with cystic fibrosis
- Differentiate between cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) based on their disease mechanisms and clinical characteristics
- Discuss the management and treatment options for individuals with cystic fibrosis
Faculty
Marrah Lachowicz-Scroggins, Ph.D.
Program Director, National Institutes of Health,
National Heart, Lung, and Blood Institute
Deepika Polineni, MD, MPH
Associate Professor of Pediatrics
Director of the Cystic Fibrosis Center, Edward Mallinckrodt Department of Pediatrics Washington University School of Medicine
Disclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Deepika Polineni, MD, MPH: Advisor to Laurent Pharmaceuticals.
Marrah Lachowicz-Scroggins, PhD: No relevant financial relationships disclosed.
Charles Vega, MD, FAAFP (Moderator): Consultant to GlaxoSmithKline.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and the National Heart, Lung, and Blood Institute of the National Institutes of Health. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supporters and Partners
Education Partner
Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.